SLC5A2 and type 1 diabetes mellitus: It may be time to rethink, verify the data, and once again reassess whether the benefits still outweigh the risks of possible treatment with SGLT-2 inhibitors in people with type 1 diabetes, as the meta-analysis by Nan et al. also suggests [6].